https://doi.org/10.4081/hmr.v2i5.735

CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 621
PDF: 2402
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

JF DiJoseph
support@pagepress.org
K Khandke
MM Dougher
DY Evans
DC Armellino
PR Hamann
NK Damle
CMC-544 (Inotuzumab ozogamicin) is a CD22-targeted immunoconjugate of calicheamicin currently being evaluated in phase III clinical trials in patients with non- Hodgkin’s B-cell lymphoma. CMC-544 is the product of a collaboration between Wyeth and UCB-Celltech. CMC-544 has demonstrated significant clinical activity in both follicular and diffuse large B-cell lymphoma patients who had failed multiple therapies.1,2 CMC-544 (Figure 1) is a humanized IgG4 anti-CD22 antibody (G5/44) covalently linked to N-acetyl gamma calicheamicin dimethyl hydrazide (CalichDMH) via an acid-labile 4-(4-acetylphenoxy)butanoic acid (AcBut) linker.3,4 CD22 is a Blymphoid lineage-specific differentiation antigen expressed on the surface of both normal and malignant B cells. CD22 is not expressed on hematopoietic progenitors of the B-lymphoid lineage. CD22 efficiently internalizes upon binding to an antibody making it an ideal candidate for targeted drug delivery. Targeting malignant B-cells through CD22 by the CD22 specific antibody G5/44 could, therefore, be an efficient way to deliver calicheamicin to destroy malignant B-cells.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

DiJoseph, J., Khandke, K., Dougher, M., Evans, D., Armellino, D., Hamann, P., & Damle, N. (2009). CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.735
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).